

Ulcerative Colitis

**How does a new medicine (efmarodocokin alfa) compare to available medicine and placebo – in people with ulcerative colitis**

<b>Trial Status</b> Completed	<b>Trial Runs In</b> 16 Countries	<b>Trial Identifier</b> NCT03558152 2017-002350-36 GA39925
----------------------------------	--------------------------------------	--

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This phase 2, randomized, double-blind, placebo-controlled, parallel-group clinical trial – was done to study “efmarodocokin alfa”, a new medicine for the treatment of patients with ulcerative colitis (UC). This study compared how well efmarodocokin alfa works in comparison to vedolizumab and placebo – when given to people with UC. One hundred and ninety-five people took part at 71 study centers in 16 countries.

<b>Genentech, Inc. (A part of F. Hoffmann-La Roche Ltd., Switzerland)</b> Sponsor	<b>Phase 2</b> Phase
--	-------------------------

---

**NCT03558152 2017-002350-36 GA39925**  
Trial Identifiers

---

***Eligibility Criteria:***

<b>Gender</b> All	<b>Age</b> >= 18 Years & <= 80 Years	<b>Healthy Volunteers</b> No
----------------------	---	---------------------------------

---